When your lungs betray you, your voice becomes your strongest tool. That’s what it means to live and speak through pulmonary fibrosis (PF). Living with PF or another rare disease involves managing various challenges that can affect time, emotional well-being, and physical health. The countless doctor appointments, procedures,…
Held back by breath: The reality of living with pulmonary fibrosis
Later this week, summer arrives. Shortly after that come the dog days of summer, usually recognized as July 3-Aug. 11. Those days are typically considered the hottest, most sultry of the year. For most of my life, I welcomed those muggy days of summer. But with my diagnosis…
Treatment with Trevi Therapeutics’ nalbuphine extended-release (ER) tablets significantly reduced daily coughing frequency in people with idiopathic pulmonary fibrosis (IPF) and chronic cough. That’s according to top-line data from the Phase 2b CORAL trial (NCT05964335), which is evaluating three doses of the experimental oral therapy against a…
The pulmonary fibrosis (PF) community is made up of people from all walks of life. This disease does not discriminate at any level. Your skin color, religious preference, gender identity, sexual orientation, ethnic background, or the size of your bank account is not a factor known to contribute to…
Let-7, an established tumor suppressor microRNA that controls gene activity, plays a key role in lung tissue repair and the development of pulmonary fibrosis (PF), which is marked by scarring of the lungs, a study discovered. Mice lacking let-7 in lung cells spontaneously develop lung injury, demonstrating that the…
If your journey with pulmonary fibrosis were a movie, what best describes the genre? Horror? Comedy? Drama? Reality? Wait, how about a Hallmark movie? When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2017, it was a complete surprise — and initially, best described…
Nerandomilast, Boehringer Ingelheim’s investigational oral therapy, significantly slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) after a year of treatment, according to final data from two Phase 3 clinical trials. FIBRONEER-IPF (NCT05321069) enrolled 1,177 IPF patients, while FIBRONEER-ILD…
I couldn’t decide whether to open my column this week with “I hate this disease” or “This disease simply isn’t fair.” It’s been one of those weeks when both statements are true. I hate this disease, and this disease isn’t fair. The first few days after my idiopathic pulmonary fibrosis…
A Phase 2 clinical trial has begun recruiting that’s assessing the safety and efficacy of LTI-03, Rein Therapeutics’ inhaled therapy for idiopathic pulmonary fibrosis (IPF). RENEW (NCT06968845) is expected to enroll up to 120 people at about 50 sites in the U.S., U.K., Germany, Austria, and Poland.
After my mid-May clinic visit, I made my 130th medication change since my bilateral lung transplant in July 2021. Each week I fill my pill boxes with 17 medications. Another 17 have come out of rotation since my transplant. Following my diagnosis of idiopathic pulmonary fibrosis in January…
